Concepedia

Author

Alexandros Georgiou

Institute of Cancer ResearchORCID

Also Known As

A Georgiou, A. Georgiou, A.J Georgiou, ALEXANDROS GEORGIOU, Alexandros Georgiou, Antonis Georgiou, Scott Edmonds

87

Publications

295

Citations

11

H-Index

28

Concepts

All Affiliations

Institute of Cancer ResearchRoyal Marsden NHS Foundation TrustCancer Research UK
AG

About

Alexandros Georgiou is an author at Institute of Cancer Research specializing in medicine, radiation oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

43

2

Health Sciences

1

1

20

3

Public Health

1

1

20

4

Cell Biology

1

1

16

5

Immunology

1

1

16

Alexandros Georgiou

×

9

Publications

184

Citations

9

H-Index

YearCitations

Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center

Alexandros Georgiou, Shelize Khakoo, Penelope Edwards,

Cancers

2019

37

Inactivation of <i>NF1</i> Promotes Resistance to EGFR Inhibition in <i>KRAS/NRAS/BRAFV600</i> -Wild-Type Colorectal Cancer

Alexandros Georgiou, Adam Stewart, David Cunningham,

Molecular Cancer Research

2020

27

Mental Health and Adherence to COVID-19 Protective Behaviors among Cancer Patients during the COVID-19 Pandemic: An International, Multinational Cross-Sectional Study

Angelos P. Kassianos, Alexandros Georgiou, Maria Kyprianidou,

Cancers

2021

22

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in <i>KRAS</i> -Mutant Cancers

Adam Stewart, Elizabeth A. Coker, Sebastian Pölsterl,

Molecular Cancer Therapeutics

2019

21

Electrical stimulation therapy in the treatment of cigarette smoking

Alexandros Georgiou, Christopher P. Spencer, GE Davies,

Journal of Substance Abuse

1998

20

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

Anna Minchom, Parames Thavasu, Zai Ahmad,

PLoS ONE

2017

16

Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age &lt; 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study

D.J. Hughes, Matthaios Kapiris, Andreja Podvez Nevajda,

Cancers

2022

16

Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma

Kok Haw Jonathan Lim, Lavinia Spain, Claire Barker,

ESMO Open

2018

14

Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC)

Heike Seifert, Alexandros Georgiou, H.Richard Alexander,

Gynecologic Oncology

2015

11

Page 1